Shares of Vectura Group PLC (LON:VEC) have been given an average recommendation of “Buy” by the ten brokerages that are covering the stock, Marketbeat reports. Three investment analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is GBX 169.14 ($2.34).
Several brokerages have recently weighed in on VEC. JPMorgan Chase & Co. reissued an “overweight” rating on shares of Vectura Group in a research report on Monday, January 15th. Shore Capital reissued a “buy” rating on shares of Vectura Group in a research report on Thursday, January 4th. Peel Hunt reissued a “hold” rating and set a GBX 160 ($2.21) price target on shares of Vectura Group in a research report on Thursday, January 4th. Numis Securities reissued a “buy” rating and set a GBX 170 ($2.35) price target on shares of Vectura Group in a research report on Thursday, January 4th. Finally, Royal Bank of Canada raised shares of Vectura Group to a “sector performer” rating and set a GBX 119 ($1.64) price target on the stock in a research report on Thursday, December 14th.
Vectura Group (LON:VEC) opened at GBX 80 ($1.11) on Tuesday. Vectura Group has a 1 year low of GBX 70.50 ($0.97) and a 1 year high of GBX 166.97 ($2.31).
Vectura Group Company Profile
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company’s products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) – LABA-LAMA; Seebri Breezhaler (EU and RoW) – LAMA; AirFluSal Forspiro (EU and RoW) – ICS-LABA; ADVATE (Global) – Antihaemophilic Factor (Recombinant); Adept (Global) – Icodextrin; Anoro Ellipta (Global) – LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) – ICS-LABA, and Incruse Ellipta (Global) – LAMA.
Receive News & Ratings for Vectura Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vectura Group and related companies with MarketBeat.com's FREE daily email newsletter.